Warning: The NCBI web site requires JavaScript to function. more...
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Hörl WH, Zlabinger GJ, Säemann MD.
Arthritis Res Ther. 2005;7(3):R694-703. Epub 2005 Apr 1.
Related citations
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.
Palmer G, Burger D, Mezin F, Magne D, Gabay C, Dayer JM, Guerne PA.
Arthritis Res Ther. 2004;6(3):R181-9. Epub 2004 Feb 19.
Inhibition of human dendritic cell maturation and function by the novel immunosuppressant FK778.
Zeyda M, Kirsch BM, Geyeregger R, Stuhlmeier KM, Zlabinger GJ, Hörl WH, Säemann MD, Stulnig TM.
Transplantation. 2005 Oct 27;80(8):1105-11.
Sex hormones modulate the effects of Leflunomide on cytokine production by cultures of differentiated monocyte/macrophages and synovial macrophages from rheumatoid arthritis patients.
Cutolo M, Montagna P, Brizzolara R, Sulli A, Seriolo B, Villaggio B, Triolo P, Clerico P, Soldano S.
J Autoimmun. 2009 May-Jun;32(3-4):254-60. Epub 2009 Mar 26.
Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.
Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Hörl WH, Waldhäusl W, Stulnig TM, Säemann MD.
Arthritis Rheum. 2005 Sep;52(9):2730-9.
Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW, Kao PN, Chao AC, Gardner P, Ng J, Morris RE.
J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 1):1016-30.
Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.
Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villaggio B.
Ann Rheum Dis. 2003 Apr;62(4):297-302.
Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Vergne-Salle P, Léger DY, Bertin P, Trèves R, Beneytout JL, Liagre B.
Cytokine. 2005 Sep 7;31(5):335-48.
Estrogens interfere with leflunomide modulation of cytokine production by human activated monocytes.
Montagna P, Soldano S, Brizzolara R, Villaggio B, Triolo P, Clerico P, Meroni M, Sulli A, Seriolo B, Molfetta L, Cutolo M.
Ann N Y Acad Sci. 2010 Apr;1193:30-5.
[An exploratory study on in vitro effects and mechanism of leflunomide on dendritic cells of systemic lupus erythematosus].
Zhang X, Zhou H, Dong GF, Shi YZ.
Zhonghua Nei Ke Za Zhi. 2005 May;44(5):370-3. Chinese.
A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools.
Huang M, Wang Y, Collins M, Mitchell BS, Graves LM.
Mol Pharmacol. 2002 Sep;62(3):463-72.
Leflunomide and malononitrilamides.
Silva Júnior HT, Morris RE.
Am J Med Sci. 1997 May;313(5):289-301. Review.
Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis.
Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S.
Inflamm Res. 2004 Oct;53(10):544-50.
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP.
Ann Rheum Dis. 2004 Sep;63(9):1056-61. Epub 2004 Apr 28.
Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
Mirmohammadsadegh A, Homey B, Abts HF, Köhrer K, Ruzicka T, Michel G.
Biochem Pharmacol. 1998 May 1;55(9):1523-9.
The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Vrenken TE, Buist-Homan M, Kalsbeek AJ, Faber KN, Moshage H.
J Hepatol. 2008 Nov;49(5):799-809. Epub 2008 Aug 22.
The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Magne D, Mézin F, Palmer G, Guerne PA.
Inflamm Res. 2006 Nov;55(11):469-75.
Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures.
Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M.
Ann Rheum Dis. 2003 May;62(5):440-3.
Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells.
Grisar J, Aringer M, Köller MD, Stummvoll GH, Eselböck D, Zwölfer B, Steiner CW, Zierhut B, Wagner L, Pietschmann P, Smolen JS.
Ann Rheum Dis. 2004 Dec;63(12):1632-7.
In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1.
Williams CR, Sykes JE, Mehl M, MacLeod JS, Lindsay LL, Poland AM, Chen YJ, Kyles AE, Waldman WJ, Gregory CR.
Am J Vet Res. 2007 Sep;68(9):1010-5.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on